A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study)

Based on many clinical and preclinical findings the ‘vigilance regulation model of mania’ postulates that an unstable regulation of wakefulness is a pathogenetic factor in both mania and Attention Deficit Hyperactivity Disorder (ADHD) and induces hyperactivity and sensation seeking as an autoregulatory attempt to stabilize wakefulness. Accordingl y, stimulant medications with their vigilance stabilizing properties could have rapid antimanic effects similar to their beneficial effects in ADHD. The MEMAP study – a multi-center, double-blind, placebo-controlled and randomized clinical trial (RCT) – assessed the antimanic efficacy and safety of a 2.5-day treatment with methylphenidate (20–40mg/day).

Source: European Neuropsychopharmacology - November 23, 2017 Category: Psychiatry & Psychology Authors: Ulrich Hegerl, Roland Mergl, Christian Sander, Jens Dietzel, Istvan Bitter, Koen Demyttenaere, Ricardo Gusm ão, Ana Gonzalez-Pinto Arrillaga, Iñaki Zorrilla, Adriana García Alocén, Victor Perez Sola, Eduard Vieta, Georg Juckel, Ulrich S. Zimmermann, M Source Type: research